全球抗凝血劑市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計抗凝血劑市場將從 2025 年的 453.4 億美元成長到 2034 年的 805.3 億美元，2026 年至 2034 年的複合年成長率為 6.59%。

由於心血管疾病和血液凝固障礙的盛行率不斷上升，全球抗凝血劑市場正經歷強勁成長。抗凝血劑是用於預防有害血栓形成的藥物，可降低中風、深層靜脈栓塞症和肺動脈栓塞等疾病的風險。人們對心血管健康的日益重視顯著推動了對這些藥物的需求。

市場的主要促進因素包括人口老化、久坐的生活方式以及心臟相關疾病的增加。醫療專業人員擴大為有血栓相關併發症風險的患者開立抗凝血劑。此外，藥物研發的進步也催生了新型抗凝血劑的出現，這些藥物比傳統治療方法更安全、更容易使用。

隨著全球醫療保健系統日益重視預防醫學和有效的心血管治療，抗凝血劑市場預計將進一步擴張。持續的研發和臨床試驗正推動更先進治療方法的開發。凝血障礙診斷技術的進步也將促進治療方法的廣泛應用。隨著健康意識的增強和醫學的進步，抗凝血劑市場有望持續成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球抗凝血劑市場：依藥物類別分類

• 市場分析、洞察與預測
• XA因子抑制劑（新型口服抗凝血藥物/直介面服抗凝血藥物）
• 肝素
• 直接凝血酶抑制劑
• 維生素K拮抗劑

第5章：全球抗凝血劑市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 注射藥物

第6章 全球抗凝血劑市場：依適應症分類

• 市場分析、洞察與預測
• 深層靜脈栓塞症
• 肺動脈栓塞
• 心房顫動和心肌梗死
• 缺血性中風
• 其他

第7章 全球抗凝血劑市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房

第8章 全球抗凝血劑市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Pfizer
  • Johnson & Johnson
  • BayerA¢a,A¯AG
  • BoehringerA¢a,A¯Ingelheim
  • Bristol MyersA¢a,A¯Squibb
  • DaiichiA¢a,A¯Sankyo
  • Sanofi
  • GlaxoSmithKline
  • AspenA¢a,A¯Pharmacare
  • PortolaA¢a,A¯Pharmaceuticals

The Anticoagulant Market size is expected to reach USD 80.53 Billion in 2034 from USD 45.34 Billion (2025) growing at a CAGR of 6.59% during 2026-2034.

The global anticoagulant market has experienced strong growth due to the rising prevalence of cardiovascular diseases and blood clotting disorders. Anticoagulants are medications used to prevent the formation of harmful blood clots, reducing the risk of conditions such as stroke, deep vein thrombosis, and pulmonary embolism. Increasing awareness of cardiovascular health has significantly boosted demand for these medications.

Key drivers of the market include aging populations, sedentary lifestyles, and increasing rates of heart-related health conditions. Healthcare providers are increasingly prescribing anticoagulants for patients at risk of clot-related complications. Advances in pharmaceutical research have also led to the development of newer anticoagulant drugs with improved safety profiles and easier administration compared to traditional treatments.

Looking ahead, the anticoagulant market is expected to expand further as global healthcare systems emphasize preventive care and effective cardiovascular treatment. Continuous research and clinical trials are leading to the development of more advanced therapies. Improved diagnostic technologies for detecting clotting disorders will also increase treatment adoption. With rising healthcare awareness and medical advancements, the anticoagulant market is likely to experience sustained growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Factor XA Inhibitors (NOAC/DOAC)
• Heparins
• Direct Thrombin Inhibitors
• Vitamin K Antagonists

By Route of Administration

• Oral
• Injectable

By Indication

• Deep Vein Thrombosis
• Pulmonary Embolism
• Atrial Fibrillation and Heart Attack
• Ischemic Stroke
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Pfizer, Johnson Johnson, BayerAG, BoehringerIngelheim, Bristol MyersSquibb, DaiichiSankyo, Sanofi, GlaxoSmithKline, AspenPharmacare, PortolaPharmaceuticals
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTICOAGULANT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Factor XA Inhibitors (NOAC/DOAC) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Heparins Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Direct Thrombin Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Vitamin K Antagonists Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANTICOAGULANT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANTICOAGULANT MARKET: BY INDICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Indication
• 6.2. Deep Vein Thrombosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Pulmonary Embolism Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Atrial Fibrillation and Heart Attack Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Ischemic Stroke Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANTICOAGULANT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ANTICOAGULANT MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Drug Class
  • 8.2.2 By Route Of Administration
  • 8.2.3 By Indication
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Drug Class
  • 8.3.2 By Route Of Administration
  • 8.3.3 By Indication
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Drug Class
  • 8.4.2 By Route Of Administration
  • 8.4.3 By Indication
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Drug Class
  • 8.5.2 By Route Of Administration
  • 8.5.3 By Indication
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Drug Class
  • 8.6.2 By Route Of Administration
  • 8.6.3 By Indication
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL ANTICOAGULANT INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Pfizer
  • 10.2.2 Johnson & Johnson
  • 10.2.3 BayerA¢a,A¯AG
  • 10.2.4 BoehringerA¢a,A¯Ingelheim
  • 10.2.5 Bristol MyersA¢a,A¯Squibb
  • 10.2.6 DaiichiA¢a,A¯Sankyo
  • 10.2.7 Sanofi
  • 10.2.8 GlaxoSmithKline
  • 10.2.9 AspenA¢a,A¯Pharmacare
  • 10.2.10 PortolaA¢a,A¯Pharmaceuticals